KRAS G12C-targeted drugs and immune responses in lung cancer
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer
This project looks at how KRAS G12C-targeted drugs change the immune response in people with KRAS G12C-mutant non-small cell lung cancer to find better drug combinations.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11191416 on NIH RePORTER |
What this research studies
From a patient's perspective, researchers are studying how KRAS G12C inhibitors re-shape the tumor immune environment using lab models and analyses of human tumor samples and blood. They will test combinations of KRAS G12C drugs with standard treatments including platinum chemotherapy and PD-1 immunotherapy to find regimens that produce longer, deeper responses. The team will also examine how other genetic changes such as STK11, KEAP1, TP53, and RBM10 influence immune effects and treatment outcomes. Findings will be used to guide which combinations should move into clinical testing.
Who could benefit from this research
Good fit: People with non-small cell lung cancer that harbors a KRAS G12C mutation, especially those eligible for KRAS G12C-targeted therapy or immunotherapy, are the ideal candidates.
Not a fit: Patients who do not have a KRAS G12C mutation or who have different cancer types are unlikely to benefit directly from this work.
Why it matters
Potential benefit: Could identify drug combinations that make KRAS G12C inhibitors work longer and improve immune control of tumors.
How similar studies have performed: KRAS G12C inhibitors have shown clinical activity and preclinical work suggests they can boost anti-tumor immunity and cooperate with PD-1 blockers, but the best combinations and mechanisms are not yet proven.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Skoulidis, Ferdinandos — University of Tx Md Anderson Can Ctr
- Study coordinator: Skoulidis, Ferdinandos
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.